Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARRIS - Another partner -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (308)	12/9/1997 12:55:00 PM
From: chirodoc	Respond to of 353

<<<<<Combine company will benefit from each part because fields are complementary and synergistic. Several new program will be open for collaboration: cancer, diabetes/obesity, inflammation, asthma (expansion of the BI deal), antibacterial/antiviral (different approach than serine protease inhibitor), expansion of cardiovascular with P&U ........that was my initial take on the deal. .......people rave so much about john walker that it seem silly that he would unify the two companies without a good long term strategy. ......and imho i think that these kinds of deals wll be commonplace because little biotech labs that are finally poducing real products will need a strong research department to feed their pipeline or team up with a big pharma. ......so let's watch for more of these mergers and acquisitions to occur in the biotech area. ......big question for us will be to see how this plays out: do we buy more? should we wait and see what happens before we do anything. thanks for you valuable input.